Activity Report and Sales Note to Accompany Appendix 4C
Melbourne (Australia) – 21 April 2020. Telix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging product
Telix Pharmaceuticals Limited today provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging product, the TLX591-CDx kit (Kit for the preparation of 68Ga-PSMA-11 Injection).
To read the full media release please click here.